Analysen von Michael J. Yee
| 07.05.12 | Xoma outperform | RBC Capital Markets | |
| 07.05.12 | XenoPort outperform | RBC Capital Markets | |
| 03.05.12 | Biogen outperform | RBC Capital Markets | |
| 02.05.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 26.04.12 | Amgen outperform | RBC Capital Markets | |
| 24.04.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 24.04.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 19.04.12 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
|
Werbung
|
|||
| 18.04.12 | ArQule outperform | RBC Capital Markets | |
| 18.04.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 16.04.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 10.04.12 | ArQule outperform | RBC Capital Markets | |
| 03.04.12 | Amgen outperform | RBC Capital Markets | |
| 03.04.12 | Biogen outperform | RBC Capital Markets | |
| 03.04.12 | Celgene outperform | RBC Capital Markets | |
| 28.03.12 | Elan outperform | RBC Capital Markets | |
| 23.03.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 22.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 20.03.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 20.03.12 | Biogen outperform | RBC Capital Markets | |
| 20.03.12 | Celgene outperform | RBC Capital Markets | |
| 20.03.12 | Xoma outperform | RBC Capital Markets | |
| 13.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 13.03.12 | Biogen outperform | RBC Capital Markets | |
| 13.03.12 | InterMune outperform | RBC Capital Markets | |
| 07.03.12 | Elan outperform | RBC Capital Markets | |
| 06.03.12 | Spectrum Pharmaceuticals outperform | RBC Capital Markets | |
| 06.03.12 | ArQule outperform | RBC Capital Markets | |
| 01.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 01.03.12 | Aveo Pharmaceuticals outperform | RBC Capital Markets | |
| 27.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 24.02.12 | Celgene outperform | RBC Capital Markets | |
| 23.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 17.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 17.02.12 | Biogen outperform | RBC Capital Markets | |
| 16.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 16.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 13.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 09.02.12 | Elan outperform | RBC Capital Markets | |
| 09.02.12 | InterMune outperform | RBC Capital Markets | |
| 06.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 02.02.12 | Elan outperform | RBC Capital Markets | |
| 02.02.12 | Biogen outperform | RBC Capital Markets | |
| 30.01.12 | Amgen outperform | RBC Capital Markets | |
| 26.01.12 | Myriad Genetics outperform | RBC Capital Markets | |
| 25.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 23.01.12 | Biogen outperform | RBC Capital Markets | |
| 23.01.12 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 20.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 19.01.12 | Xoma outperform | RBC Capital Markets | |